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Abstract 
A workshop was convened by a panel of psychiatrists, diabetologists and pharmacists from major Belgian 
hospitals to review the latest information relating to the risks with second-generation antipsychotics (SGA) for 
the development of metabolic disorders, especially impaired glucose tolerance, diabetes mellitus and 
dyslipidemia. The panelists sought to formulate recommendations for practising psychiatrists when initiating and 
maintaining therapy with SGA, and for the switch of SGA or initiation of further treatment if metabolic 
complications occur. In addition, recommendations for counselling of the patient and for the cooperation 
between the psychiatrist and the general physician or diabetologist, respectively, were provided. 
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INTRODUCTION 
Objectives of the workshop 
On 31 March, 10 May, and 5 July 2004 a three-part workshop was held in the University Centre of St.-Jozef in 
Belgium with the purpose to discuss important metabolic issues faced by patients on antipsychotic drugs. The 
meeting was scheduled against the background of a series of reports and mostly retrospective studies, suggesting 
a substantially increased risk for impaired glucose regulation, weight gain, manifest diabetes mellitus, and 
dyslipidemia at least for some of the second-generation antipsychotics (SGA). These risk factors and markers are 
closely associated with increased cardiovascular risk. However, there are still many unanswered questions 
concerning this issue and more research has been recommended recently by both the American Psychiatric 
Association in cooperation with the American Diabetes Association [1], as well by a British working group that 
published the consensus in the British Journal of Psychiatry [2]. 
The recently published consensuses for the management of metabolic complications associated with SGA might 
be insufficiently sensitive: in light of our data [3], it seems that screening with fasting glucose misses a number 
of patients with impaired glucose metabolism and, taking into account the possibility of possible reversal of the 
metabolic complication with early withdrawal of the incriminated medication, metabolic screening should be 
more frequent during the first 6 months; also the importance of the hyperlipidemia demands more frequent 
monitoring. 
A group of 17 invited participants, including psychiatrists, pharmacists, endocrinologists/diabetologists, and 
general physicians discussed the current state of knowledge (for full details, see appendix). On the basis of the 
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Structure of the report 
The report is divided into two sections. The first section provides a brief overview of the topics that were 
presented and considered by the participants at the meeting. The second section summarizes the consensus 
reached and the recommendations arising. 
BACKGROUND 
First- and second-generation antipsychotics 
Schizophrenia certainly is a severe and devastating mental illness, and is characterised by a chronic and recurrent 
natural course. This disease which has a lifetime prevalence of approximately 1 % worldwide is associated with 
high morbidity and mortality. Antipsychotic medications are the mainstay of treatment for psychotic illnesses. 
Following the introduction of the first-generation antipsychotics about half a century ago, these drugs have 
helped millions of people manage their symptoms. For people who respond well, antipsychotics mean the 
difference between leading an engaged, fulfilling community life and being severely disabled [1]. 
The introduction of SGA has profoundly changed the treatment of schizophrenia. SGA are as or even more 
effective and have - in general - more favourable safety profiles than those achieved with the conventional 
antipsychotics. A substantial gain has been obtained for extrapyramidal symptoms and dyskinesia, whose 
incidence is much lower with SGA. 
As a consequence, with the exception of clozapine, they have become the first line agents for their indicated use. 
Besides that, they are increasingly used in other indications such as bipolar disorder, dementia, psychotic 
depression, personality disorders and posttraumatic stress disorder [1]. In view of the high prevalence of these 
disorders, SGA are widely used medications, and their use has important public health implications. 
Diabetes mellitus: definitions 
Diabetes mellitus is a prevalent multisystem metabolic disease which is characterised by elevated blood glucose 
levels and by micro- and macrovascular complications that substantially increase the morbidity and mortality 
associated with the disease and reduce the quality of life [4]. Microvascular complications comprise retinopathy 
and nephropathy, while macrovascular complications include coronary heart disease, stroke and peripheral 
arterial disease. Peripheral neuropathy is frequently associated with the diabetic foot. 
The major types of diabetes are type 1 and type 2 diabetes [5]. Type1 diabetes is caused by the autoimmune 
destruction of the pancreatic β cells and characterized by total reliance on exogenous insulin for survival. While 
type 1 diabetes usually occurs in adolescent patients, recent research suggests that autoimmune forms of diabetes 
might be the underlying cause for up to 10-15% of cases in adults and the elderly, respectively (type 1.5 diabetes 
[6], latent diabetes in adults [7]).Type 2 diabetes, accounting for 90% of all cases, results from impaired insulin 
secretion from the β cells and resistance to the action of insulin. 
The natural history of diabetes includes an asymptomatic preclinical phase, which is characterised by impaired 
glucose regulation. The terms "impaired glucose tolerance" (IGT) and "impaired fasting glucose" (IFG) represent 
metabolic states intermediate between normal glucose homeostasis and diabetic hyperglycemia [8]. Both IGT 
and IFG are considered as risk categories for the future development of diabetes and cardiovascular diseases and 
premature death. For example, up to half of all people with IGT will progress to type 2 diabetes within 10 years 
of diagnosis. IGT and IFG are components of the metabolic syndrome, thereby heightening the patient's risk [8]. 
Table Ia displays the diagnostic criteria for diagnosis of IGT, IFG, and diabetes. 
Association of schizophrenia and antipsychotics with metabolic disorders  
The current literature supports that schizophrenia (and other psychiatric disorders such as bipolar disorders) 
appear to be associated with a higher prevalence of type 2 diabetes. Because of the silent nature of diabetes 
mellitus, and the fact that schizophrenic patients are not screened comprehensively for the disease, the true 
prevalence of hyperglycemia and diabetes may be substantially underestimated [9,10]. Notably, it has been 
suggested that schizophrenia as such carries an increased risk, as certain characteristics of schizophrenic patients 
such as unhealthy life style (e.g., true and perceived stress, eating habits, overweight, and sedentary lifestyle) 
promote the risk of diabetes. 
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This risk may be increased by antipsychotic drug treatment, as was already suggested for first-generation 
antipsychotics (FGA) [11]. The amount of literature on the association of SGA and metabolic disorders is much 
larger than for FGA; however, well-controlled prospective data are sparse. Reports comprise abnormal glucose 
regulation, exacerbation of existing type 1 and type 2 diabetes, new-onset pseudo-type 1 or type 2 diabetes, 
diabetic ketoacidosis, coma and death. In a number of large-scale studies (mostly retrospective by nature), 
reviews and meta-analyses, the association was not found for all drugs [12-18]. 
According to recent reviews, the risk of developing diabetes was highest for clozapine and olanzapine, followed 
by, quetiapine and risperidone [1, 19-23]. The hierarchy of liability of weight gain due to antipsychotics was in 
the same described order. 
 
Table Ia. Values for diagnosis of diabetes mellitus and other categories of hyperglycaemia according to WHO. 
Glucose concentration, mmol l-1      (mg dl-1) 
Whole blood Plasma* 
 
Venous Capillary Venous 
Diabetes Mellitus: 
   Fasting or ≥6.1 (≥110) ≥6.1 (≥110) ≥7.0 (≥126) 
   2-h post glucose load or both ≥10.0 (≥180) ≥11.1 (≥200) ≥11.1 (≥200) 
Impaired Glucose Tolerance (IGT) : 
   Fasting (if measured) and <6.1 (<110) <6.1 (<110) <7.0 (<126) 
   2-h post glucose load ≥6.7 (≥120) and ≥7.8 (≥ 140) and ≥7.8 (≥140) and 
 <10.0 (<180) < 11.1 (<200) < 11.1 (<200) 
Impaired Fasting Glycaemia (IFG): 
   Fasting and (if measured) ≥5.6 (≥100) and ≥5.6 (≥100) and ≥6.1 ( ≥ 110) and 
 <6.1 (<110) <6.1 (<110) <7.0 (<126) 
   2-h post glucose load <6.7 (<120) <7.8 (<140) <7.8 (<140) 
Source: World Health Organisation 1999 [5]. 
*Corresponding values for capillary plasma are: for Diabetes Mellitus, fasting >7.0 (>126), 2-h ≥ 12.2 (≥220); for impaired Glucose 
Tolerance, fasting <7.0( <126) and 2-h ≥8.9 ( >160) and < 12.2 ( <220); and for Impaired Fasting Glycaemia ≥6.1 ( ≥110) and <7.0 ( <126) 
and if measured, 2-h  <8.9 ( <160). 
*If fasting blood glucose is ≥ 126mg/dl, confirmed by a repeat testing performed on a different day, the threshold for the diagnosis of 
diabetes is met. 
Notes: IGT and IFG are not mutually exclusive, and may occur in the same patient. 
The American Diabetes Association has recently established a cutpoint of ≥ 100 mg/dl, above which persons have either IFG or diabetes 
[45]. 
 
Indeed, and in accordance with the observation of weight gain being a risk factor for glucose metabolism 
disorders in the general population, weight gain was identified in a study performed on the WHO database as a 
risk factor for antipsychotic-induced glucose intolerance [24]. However, only 5.6% of patients with glucose 
intolerance experienced weight gain. Therefore, while some of this effect is mediated through increased 
adiposity, there is evidence for an independent effect of these agents on insulin resistance/production and on 
lipidemia. 
In order to give an indication about the size of the problem, Koller et al., in an extensive pharmacovigilance 
survey, queried the Food and Drug Administration (FDA) MedWatch system for cases of hyperglycemia and 
diabetes mellitus associated with clozapine [25], olanzapine [26], risperidone [27] and quetiapine [28], and 
pooled the results with published cases. The results on olanzapine serve as an example: 237 olanzapine-
associated cases of diabetes or hyperglycemia were reported between 1994 and 2001. Of these, 188 were new-
onset diabetes, 44 were exacerbations of preexistent disease, and five could not be classified. Incidental diabetes 
occurred between 2 days and 45 months after treatment initiation (for 73% less than 6 months), while no 
correlation was found between dose and glucose level or dose and time to onset. Eighty patients had metabolic 
acidosis or ketosis, 41 had glucose levels of ≥ 1000 mg/dl, and 15 patients died. When olanzapine was 
discontinued or the dosage decreased, 78% had improved glycemic control [26]. 
Underlying mechanisms may include the following: direct genetic effect, decreased insulin sensitivity 
independent of SGA medication, increased insulin resistance related to SGA, decreased insulin production, 
effects of SGA on 5-HT2c receptors [19]. 
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Apart from disturbances in glucose metabolism, further frequent metabolic abnormalities in schizophrenic 
patients on SGA include features of the metabolic syndrome [29, 30]. Diagnostic criteria are summarized in 
Table Ib. Dyslipidemia is a feature of type 2 diabetes, and antipsychotics such as clozapine and olanzapine have 
also been associated with hypertriglyceridemia [29], while agents such as haloperidol, risperidone, and 
ziprasidone were associated with reductions in plasma triglycerides [31]. 
Amisulpride, aripiprazole, and ziprasidone seem to carry the lowest risk for weight gain and effects on insulin 
resistance. 
As a consequence, there is a shift in attention toward physical health monitoring in patients with mental health 
disorders [32-35]. The American Psychiatric Association and American Diabetes Association have recently 
published the findings on SGA and metabolic abnormalities in a joint statement (Table Ic) [29]. 
Situation in Belgium, according to a prospective study 
In the U.C. St-Jozef, currently a large prospective study (at this moment, including 250 patients) until today on 
metabolic disturbances in non-diabetic schizophrenic patients is ongoing. An oral glucose tolerance   test    
(OGTT)   was   performed in all patients. The aim is to follow patients included in the study prospectively for 1 
year, and to retest them at regular intervals (including a repeat OGTT). 
Table Ib. ATP III Clinical identification of the metabolic syndrome. 
Risk Factor Defining Level 
Abdominal obesity, given as waist circumference*† 
   Men >102 cm 
   Women >88 cm 
Triglycerides ≥150 mg/dl 
HDL cholesterol 
   Men <40 mg/dl 
   Women <50 mg/dl 
Blood pressure ≥130/ ≥ 85 mm Hg 
Fasting glucose ≥ 110 mg/dl** 
Source: National Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (NCEP) Adult Treatment Program III 
[36]. 
*Overweight and obesity are associated with insulin resistance and the metabolic syndrome. However, the presence of abdominal obesity is 
more highly correlated with the metabolic risk factors than is an elevated BMI. Therefore, the simple measure of waist circumference is 
recommended to identify the body weight component of the metabolic syndrome. 
† Some patients can develop multiple metabolic risk factors when the waist circumference is only marginally increased, e.g., in men 94-102 
cm, in women 80-88 cm. Such patients may have a strong genetic contribution to insulin resistance. They should benefit from changes in life 
habits, similarly to men with categorical increases in waist circumference. 
**The American Diabetes Association has recently established a cutpoint of ≥ 100 mg/dl, above which persons have either IFG or diabetes 
[45]. This new cutpoint should be applicable for identifying the lower boundary to define an elevated glucose as one criterion for the 
metabolic syndrome. 
 
A preliminary cross-sectional analysis on 100 schizophrenic patients (mean age 38 years and stable on 
medication for more than 6 months), showed glucose abnormalities in 22% of patients [3]: 4% met criteria of 
diabetes (of whom two patients had glucose values above 200 mg/dl at 120 min after glucose load, both with 
IFG), 16% met criteria of IGT and 2% had IFG without other glucose abnormalities. Of these relatively young 
patients, 22%    met   ATP-III criteria for the metabolic syndrome, as published by the Expert Panel on 
Detection, Evaluation and Treatment of Blood Cholesterol in adults (for criteria see Table II) [36]. Fourteen of 
the 16 patients with IGT had normal fasting glucose levels while, as a group, patients with IGT had significantly 
higher fasting insulin levels compared to patients with normal glucose tolerance (P = 0.0003). 
A monitoring protocol based only on fasting glucose would have accounted for only 12.5% of IGT and half of 
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Table Ic.  SGA and metabolic abnormalities. 
Drug Weight gain Risk for diabetes Worsening lipid profile 
Clozapine + + + + + 
Olanzapine + + + + + 
Risperidone + + ? ? 
Quetiapine ± ? ? 
Ziprasidone ± No report No report 
Amisulpride* ± No report No report 
Source: American Psychiatric Association (APA) and American Diabetes Association (ADA) 2004 [1]. 
According to existing evidence: + = increase effect, -=no effect, ? = discrepant results. 
Aripiprazole was omitted, as not marketed in Belgium. 
*Amisulpride was added to the table, risk assessment is according to consensus of the Belgian group. 
 
Regulatory situation 
The various regulatory authorities have translated the current evidence differently in the labelling text. Although 
aripiprazole and ziprasidone had no case report of hyperglycemia, the FDA has imposed a uniform labelling to 
all SGA on the US market (clozapine, olanzapine, quetiapine, ziprasidone, aripiprazole, risperidone): 
"Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death has 
been reported in patients treated with atypical antipsychotics" [38]. As for Europe, the olanzapine and 
risperidone labels approved by the Committee for Proprietary Medicinal Products (CPMP) - and the Belgian 
health authorities - mention the hyperglycemia and diabetes risk. No mention of these conditions is made with 
amisulpride and quetiapine. 
CONSENSUS STATEMENTS AND RECOMMENDATIONS 
1. How should the basic metabolic risk be managed? 
Untreated patients with schizophrenia in comparison to healthy individuals have an increased basic risk to 
develop metabolic disorders. Notably, they are to a certain extent predisposed to develop diabetes mellitus. 
Therefore, a comprehensive approach should be taken. 
The initial visit before prescribing a SGA to a patient is of particular importance, and patients having risk factors 
for metabolic complications should be identified early. Their family and metabolic history should be elucidated 
by the psychiatrist in detail. Using the categories in Table III might prove helpful for the treating physician for 
identifying susceptible patients. 
 
Table II. ATP III Classification of LDL, total and HDL cholesterol (mg/dl). 
LDL 
   <100 Optimal 
   100-129 Near or above optimal 
   130-159 Borderline high 
   160-189 High 
   >190 Very high 
Total cholesterol 
   <200 Desirable 
   200-239 Borderline high 
   ≥240 High 
HDL 
   <40 Low 
   >60 High 
LDL, density lipoprotein; HDL, high density lipoprotein. Source: National Panel on Detection, Evaluation and Treatment of High Blood 
Cholesterol in Adults (NCEP) Adult Treatment Program III [36]. 
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The psychiatrist should also initiate the laboratory screening. Measuring the fasting blood glucose is the 
minimum (for diagnostic criteria, refer to Table Ia). To increase sensitivity of screening, fasting insulin can be 
measured and insulin sensitivity in the homeostatic model (HOMA-IR) calculated [39]. Calculation of insulin 
resistance (HOMA-IR) from fasting glucose and fasting insulin has been suggested to be of value for prediction 
of diabetes in the above-mentioned Belgian prospective study [3]. However, insulin levels are not standardised 
and insulin measurements are not part of the standard screening protocol. 
The OGTT is the gold standard screening test in high risk populations (identified by medical history), but under 
daily practice conditions, the fasting plasma glucose test is more convenient [40]. However, it lacks sensitivity 
and may miss a number of patients with diabetes [3]. The HbAlc (glycosylated haemoglobin) is an 
acknowledged measure of average glycemic control for the preceding 6-8 weeks, but is not suitable to screen 
patients for diabetes. 
While looking for risk factors for developing diabetes in the patient, it is important to note that predictors for the 
most severe cases (ketoacidosis) -which are unusual - are not known. 
In choosing between SGA with equal efficacy, an SGA considered to have a low propensity for weight gain and 
diabetes is to be preferred (such as amisulpride, aripiprazole, or ziprasidone, see Table Ic). If SGA with a high 
risk for metabolic effects are indicated, the follow-up should be close, and the treating general practitioner 
(GP)/internist should be informed. 
Smoking cessation should be advised in all patients because of the convincing documentation of the causal link 
between smoking and health risk. In addition, it is known that smoking impairs glucose transport. As substantial 
weight gain can occur after stopping smoking, smoking cessation counselling should be a routine component of 
care. For details of the recommendations for the visit before starting SGA see Table IV. 
Table III. Risk factors/profile for development of cardiovascular and metabolic disorders. 
Medical factors obesity, dyslipidemia, hypertension, smoking, hyperglycemia, 
diabetes 
Behavioural factors poor diet, smoking, physical inactivity, high stress 
Genetic factors ethnicity, family history or metabolic or cardiovascular disease 
Adapted from Casey et al. [22]. 
 
2.  How should patients on SGA be followed up? 
Patients should be counselled about measuring and charting their own weight and waist circumference. Patients 
on SGA should undergo regular laboratory blood testing of blood sugar, blood lipids, as well as body weight and 
blood pressure. Table V displays the recommended time intervals between measurements of these parameters. 
3.  How to proceed when the patient develops SGA associated IFG or diabetes? 
If IFG ( ≥ 100 mg/dl) is detected, confirmed by a retest on another day, risk factors should be evaluated, and the 
frequency of follow-up examinations increased. A GP or specialist should be consulted. The calculation of 
HOMA-IR as well as an OGTT should be considered. Depending on the results, it should be considered to 
switch the patient to an SGA that has not been associated with significant weight gain or diabetes (see Table Ic). 
In addition to lifestyle changes and diet, in patients with IFG the administration of metformin to prevent 
progression to overt diabetes may be considered. 
If fasting blood glucose ≥ 126 mg/dl is confirmed on another day (i.e., diabetes diagnosis), the patient should be 
switched to a SGA that has not been associated with significant weight gain or diabetes (see Table Ic). If a 
switch of medication is not possible (e.g., patients on clozapine), diabetes has to be treated with non-drug 
(lifestyle modification, diet) or drug treatment (oral antidiabetic drugs or insulin). The consultation of a GP or 
internist/ endocrinologist is recommended. 
If the diagnosis of diabetes is made, it may in some cases be reversible if drugs are withdrawn early. 
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Table IV. Components of the visit before prescription of SGA. 
Medical history, focussing on metabolic problems and on family history 
•    Symptoms, results of laboratory tests, and special 
examinations, if any, related to the diagnosis of diabetes 
•    Prior fasting blood glucose, OGTT, or HbAlc records 
•    Family history of diabetes or overweight/obesity 
•    Eating patterns, nutritional status, weight history 
•    Exercise history 
•    Other medications or drugs affecting blood glucose levels (valproate, lithium, etc.) 
•    Risk factors for atherosclerosis: smoking, hypertension, obesity, dyslipidemia, and family 
history 
•    Prior nutrition education, attitudes, and health beliefs 
•    Tobacco, alcohol abuse and/or controlled substance use Physical examination 
•    Measurement of height and weight, calculation of Body Mass Index 
•    Waist circumference* 
•    In-depth physical examination 
•    Blood pressure 
Laboratory examination 
•    Fasting plasma glucose 
•    Fasting lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides) 
Counselling 
•    on the diabetic risk associated with the underlying disease and with SGA 
•    on signs of ketoacidosis and other diabetic complications 
•    on life styles issues (smoking cessation, nutrition, self-monitoring of weight) 
*To be measured in the middle between iliac crest and lower rib cartilage. 
OGTT, oral glucose tolerance test. 
 
Table V. Recommended schedule of monitoring for patients taking SGA. 
Weight and waist 
circumference 
Weekly in hospital care, monthly in ambulatory care 
Fasting blood glucose* Depending on risk factors and drugs**. 
 Monthly in patients with family history of diabetes/obesity and/or with manifest 
overweight or obesity, and/or with impaired fasting glucose, 
 After 6 and 12 weeks, then quarterly in patients without risk factors 
Fasting blood lipids Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides 
 Every 3 months for the first year of treatment, then annually 
Blood pressure Every 3 months 
*Fasting is defined as no caloric intake for at least 8 h. 
**Also if the risk factors weight gain and IFG occur anew. 
Note: in patients on classical antipsychotics and with addition risk factors, a similar follow-up schedule should be observed. 
 
4.  Management of SGA-induced dyslipidemia 
In patients who develop dyslipidemia while on SGA therapy (for reference values, see ATP III recommendations 
in Table Ib and II), after a confirmatory lab test, a diet should be tried. If no satisfactory effect is achieved, a 
switch to SGA with a lower risk of metabolic side effects is recommended (see Ic). If a medication change is 
contraindicated, a GP or specialist should be consulted, who will initiate further treatment steps (e.g., lipid-
lowering medication). 
5.  Management of SGA-induced obesity 
Weight gain should be prevented by choosing a safe SGA in overweight patients. Patients should be counselled 
on lifestyle changes and dietary measures at the initiation of and during antipsychotic therapy. Concerning diet 
and exercise, patients should (a) decrease the fat and energy content of their diet and increase fibre intake, (b) eat 
more fruits and vegetables, (c) eat complex rather than simple carbohydrates, (d) avoid sugary drinks, and (e) 
exercise for at least 10-15 min per day [41], ideally 30 min per day [42]. In patients with significant weight gain 
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(≥7%), a change of medication to a drug that is associated with a lesser weight gain should be considered. If no 
satisfactory treatment effect is achievable, a GP's or internist's and/or dietetician's advice should be sought. In 
terms of drug-treatment for being overweight, orlistat is expensive and problems in absorption of antipsychotics 
may occur; sibutramine has been suspected to induce psychotic symptoms and is contraindicated for individuals 
with psychiatric disorders. 
6.  Which recommendations can be given for patients with other mental disorders treated with SGA? 
SGA are used in a broad spectrum of indications, including bipolar disorder, psychotic depression, dementia, 
autism, developmental delay, and others [1, 14]. Data on the relationship between mental disorders other than 
schizophrenia and metabolic disorders are limited. However, certain patient groups, e.g., those with mood 
disorders, also appear to be at increased risk [14, 43, 44]. Accordingly, a cautious attitude is recommended: these 
patients should also be screened and monitored as described above. Patients with medications known to increase 
the risk of weight gain, such as mood stabilizers, should be closely followed-up. Patients and their families or 
caregivers should be counselled about the possible metabolic complications. If those occur, change of medication 
to drugs with a lower metabolic risk should be considered. 
7.  How should the patient be informed about the metabolic effects of SGA? 
When starting treatment with SGA, the need of antipsychotic maintenance therapy, the risks of not taking any 
medications, and the advantages of SGAs should be discussed with the patient. By the same token, the patient 
should be counselled on the metabolic risk of the underlying disease and the risks associated the planned drug 
SGA treatment. Patient information includes the risk of diabetes and IFG, weight gain, and dyslipidemia, and 
measures to prevent these conditions (lifestyle changes, diet). 
Since diabetic ketoacidosis cannot be foreseen, patient education on this condition is mandatory. Specifically, the 
patient, family members and caregivers must be educated about the warning signs of the acute decompensation 
of diabetes, as it is life-threatening, albeit infrequent. Diabetic ketoacidosis includes the rapid onset of polyuria 
and polydipsia, weight loss, nausea and vomiting, dehydration, rapid respiration, and sensory clouding, leading 
to coma. 
8. Recommendations for the collaboration between the psychiatrist with the GP or the diabetologist 
According to the present recommendations, the psychiatrist initiates the screening and follow-up measures. If 
tests, however, indicate impaired glucose metabolism, diabetes, dyslipidemia, or hypertension, the future 
management of these physical diseases should be primarily provided by a GP or internist/diabetologist. Close 
communication should be maintained by the psychiatrist and GP, especially concerning change or maintenance 
of medications. 
The primary goal of therapy is to achieve best control of the mental disease of the patient. Nonetheless, 
metabolic control should be aimed at as well. 
Key points 
•    SGA with the lowest risk profile (amisulpride, aripiprazole, ziprasidone) are to be preferred 
•   Patients having risk factors for metabolic complications should be identified early, before SGA initiation 
•   Frequency of the monitoring should be adapted to the metabolic status (risk factors; pre-existing obesity, 
hyperlipidaemia or glucose metabolism disorders) of the patient and to the metabolic risk profile associated to 
the chosen SGA 
•   Treatment-emergent metabolic disorders warrant switch of the SGA to a lower risk profile-associated agent 
and management of the complication in collaboration with the GP/endocrinologist 
•   Patients should be informed about the management of their mental illness and the metabolic risk associated to 
SGA 
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